These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 25262379)

  • 21. A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors.
    Cao J; Zhang J; Peng W; Chen Z; Fan S; Su W; Li K; Li J
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):259-69. PubMed ID: 27299749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors.
    Hong D; Said R; Falchook G; Naing A; Moulder S; Tsimberidou AM; Galluppi G; Dakappagari N; Storgard C; Kurzrock R; Rosen LS
    Clin Cancer Res; 2013 Sep; 19(17):4824-31. PubMed ID: 23873691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.
    Chandarlapaty S; Sawai A; Ye Q; Scott A; Silinski M; Huang K; Fadden P; Partdrige J; Hall S; Steed P; Norton L; Rosen N; Solit DB
    Clin Cancer Res; 2008 Jan; 14(1):240-8. PubMed ID: 18172276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers.
    Yap TA; Yan L; Patnaik A; Tunariu N; Biondo A; Fearen I; Papadopoulos KP; Olmos D; Baird R; Delgado L; Tetteh E; Beckman RA; Lupinacci L; Riisnaes R; Decordova S; Heaton SP; Swales K; deSouza NM; Leach MO; Garrett MD; Sullivan DM; de Bono JS; Tolcher AW
    Clin Cancer Res; 2014 Nov; 20(22):5672-85. PubMed ID: 25239610
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
    Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
    Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies.
    Goldman JW; Raju RN; Gordon GA; El-Hariry I; Teofilivici F; Vukovic VM; Bradley R; Karol MD; Chen Y; Guo W; Inoue T; Rosen LS
    BMC Cancer; 2013 Mar; 13():152. PubMed ID: 23530663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
    Wicki A; Brown N; Xyrafas A; Bize V; Hawle H; Berardi S; Cmiljanović N; Cmiljanović V; Stumm M; Dimitrijević S; Herrmann R; Prêtre V; Ritschard R; Tzankov A; Hess V; Childs A; Hierro C; Rodon J; Hess D; Joerger M; von Moos R; Sessa C; Kristeleit R
    Eur J Cancer; 2018 Jun; 96():6-16. PubMed ID: 29660598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study.
    Saka H; Kitagawa C; Kogure Y; Takahashi Y; Fujikawa K; Sagawa T; Iwasa S; Takahashi N; Fukao T; Tchinou C; Landers D; Yamada Y
    Invest New Drugs; 2017 Aug; 35(4):451-462. PubMed ID: 28070720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
    Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
    Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.
    Amorim S; Stathis A; Gleeson M; Iyengar S; Magarotto V; Leleu X; Morschhauser F; Karlin L; Broussais F; Rezai K; Herait P; Kahatt C; Lokiec F; Salles G; Facon T; Palumbo A; Cunningham D; Zucca E; Thieblemont C
    Lancet Haematol; 2016 Apr; 3(4):e196-204. PubMed ID: 27063978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study.
    Czito BG; Deming DA; Jameson GS; Mulcahy MF; Vaghefi H; Dudley MW; Holen KD; DeLuca A; Mittapalli RK; Munasinghe W; He L; Zalcberg JR; Ngan SY; Komarnitsky P; Michael M
    Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):418-426. PubMed ID: 28497757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours.
    Spicer J; Baird R; Suder A; Cresti N; Corbacho JG; Hogarth L; Frenkel E; Matsumoto S; Kawabata I; Donaldson K; Posner J; Sarker D; Jodrell D; Plummer R
    Eur J Cancer; 2015 Jan; 51(2):137-45. PubMed ID: 25434923
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
    Infante JR; Fecher LA; Falchook GS; Nallapareddy S; Gordon MS; Becerra C; DeMarini DJ; Cox DS; Xu Y; Morris SR; Peddareddigari VG; Le NT; Hart L; Bendell JC; Eckhardt G; Kurzrock R; Flaherty K; Burris HA; Messersmith WA
    Lancet Oncol; 2012 Aug; 13(8):773-81. PubMed ID: 22805291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors.
    Infante JR; Mendelson DS; Burris HA; Bendell JC; Tolcher AW; Gordon MS; Gillenwater HH; Arastu-Kapur S; Wong HL; Papadopoulos KP
    Invest New Drugs; 2016 Apr; 34(2):216-24. PubMed ID: 26924128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours.
    Schöffski P; Jones SF; Dumez H; Infante JR; Van Mieghem E; Fowst C; Gerletti P; Xu H; Jakubczak JL; English PA; Pierce KJ; Burris HA
    Eur J Cancer; 2011 Oct; 47(15):2256-64. PubMed ID: 21852114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours.
    Schöffski P; Delord JP; Brain E; Robert J; Dumez H; Gasmi J; Trouet A
    Eur J Cancer; 2017 Nov; 86():240-247. PubMed ID: 29055839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.
    Leijen S; Middleton MR; Tresca P; Kraeber-Bodéré F; Dieras V; Scheulen ME; Gupta A; Lopez-Valverde V; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Schellens JH; Eberhardt WE
    Clin Cancer Res; 2012 Sep; 18(17):4794-805. PubMed ID: 22767668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.
    Boss DS; Schwartz GK; Middleton MR; Amakye DD; Swaisland H; Midgley RS; Ranson M; Danson S; Calvert H; Plummer R; Morris C; Carvajal RD; Chirieac LR; Schellens JHM; Shapiro GI
    Ann Oncol; 2010 Apr; 21(4):884-894. PubMed ID: 19825886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors.
    Diamond JR; Bastos BR; Hansen RJ; Gustafson DL; Eckhardt SG; Kwak EL; Pandya SS; Fletcher GC; Pitts TM; Kulikowski GN; Morrow M; Arnott J; Bray MR; Sidor C; Messersmith W; Shapiro GI
    Clin Cancer Res; 2011 Feb; 17(4):849-60. PubMed ID: 21131552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.